Immupharma Plc Stock Earnings Per Share
| IMM Stock | 1.12 0.01 0.88% |
ImmuPharma PLC fundamentals help investors to digest information that contributes to ImmuPharma PLC's financial success or failures. It also enables traders to predict the movement of ImmuPharma Stock. The fundamental analysis module provides a way to measure ImmuPharma PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmuPharma PLC stock.
ImmuPharma | Earnings Per Share |
ImmuPharma PLC Company Earnings Per Share Analysis
ImmuPharma PLC's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current ImmuPharma PLC Earnings Per Share | (0.01) X |
Most of ImmuPharma PLC's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmuPharma PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
ImmuPharma Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, ImmuPharma PLC has an Earnings Per Share of -0.01 times. This is much lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The earnings per share for all United Kingdom stocks is notably higher than that of the company.
ImmuPharma Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmuPharma PLC's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImmuPharma PLC could also be used in its relative valuation, which is a method of valuing ImmuPharma PLC by comparing valuation metrics of similar companies.ImmuPharma PLC is currently under evaluation in earnings per share category among its peers.
ImmuPharma Fundamentals
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.43 | ||||
| Operating Margin | 36.15 % | ||||
| Current Valuation | 4.49 M | ||||
| Shares Outstanding | 416.44 M | ||||
| Shares Owned By Insiders | 48.33 % | ||||
| Shares Owned By Institutions | 14.35 % | ||||
| Price To Book | 1.75 X | ||||
| Price To Sales | 60.75 X | ||||
| Gross Profit | 118.35 K | ||||
| EBITDA | (3.03 M) | ||||
| Net Income | (2.92 M) | ||||
| Total Debt | 1.67 M | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (1.36 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 5.0 | ||||
| Beta | 1.58 | ||||
| Market Capitalization | 4.81 M | ||||
| Total Asset | 2.72 M | ||||
| Retained Earnings | (64.08 M) | ||||
| Working Capital | (321.92 K) | ||||
| Net Asset | 2.72 M |
About ImmuPharma PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmuPharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuPharma PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuPharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in ImmuPharma Stock
ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.